Beneficial effects of the vasopeptidase inhibitor omapatrilat on neurogenic volume retention in rats with experimental congestive heart failure (CHF)

被引：0
|
作者：
Klanke, B [1 ]
Karl, HF [1 ]
Ditting, T [1 ]
Schmieder, RE [1 ]
Veelken, R [1 ]
机构：
[1] Univ Erlangen Nurnberg, Erlangen, Germany
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：512A / 512A
页数：1
相关论文
共 50 条
  • [1] Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure
    Abassi, ZA
    Yahia, A
    Zeid, S
    Karram, T
    Golomb, E
    Winaver, J
    Hoffman, A
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2005, 288 (02): : H722 - H728
  • [2] Effects of omapatrilat, a vasopeptidase inhibitor, on renal function and cardiac hypertrophy in rats with experimental heart failure.
    Abassi, Z
    Yahia, A
    Zeid, S
    Hayek, T
    Winaver, J
    Hoffman, A
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 514A - 514A
  • [3] Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with heart failure: Comparison with enalapril
    Abassi, ZA
    Zeid, S
    Yahia, A
    Winaver, J
    Hoffman, A
    AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (05) : 84A - 84A
  • [4] Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats
    Wenzel, UO
    Wolf, G
    Jacob, I
    Schwegler, C
    Qasqas, A
    Amann, K
    Helmchen, U
    Stahl, RAK
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (10) : 2005 - 2013
  • [5] Vasopeptidase inhibitor, omapatrilat, improved cardiac function and remodelling in rats with chronic heart failure
    Maki, T
    Nasa, Y
    Tanonaka, K
    Takeo, S
    JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 88 : 78P - 78P
  • [6] Beneficial effects of vasopeptidase inhibition on mortality and morbidity in heart failure: Evidence from the omapatrilat heart failure program
    Kostis, JB
    Rouleau, JL
    Pfeffer, MA
    Rousseau, MF
    Ikram, H
    Komajda, M
    Qian, CL
    Block, AJ
    Hanyok, JJ
    Synhorst, DP
    Pouleur, H
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 240A - 240A
  • [7] A comparison of the vasopeptidase inhibitor omapatrilat vs lisinopril in subjects with heart failure
    Kostis, J
    Rouleau, JL
    Pfeffer, MA
    Rousseau, MF
    Ikram, H
    Komajda, M
    EUROPEAN HEART JOURNAL, 2000, 21 : 344 - 344
  • [8] Congestive heart failure (CHF) does not affect steady-state (SS) pharmacokinetics (PK) of omapatrilat (OMA), a vasopeptidase inhibitor (VPI), and its metabolites (M).
    Malhotra, BK
    Klapholtz, M
    Delaney, CL
    Jemal, M
    Cohen, MB
    Hanyok, JJ
    Liao, WC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 136 - 136
  • [9] The antihypertensive and antihypertrophic effects of the vasopeptidase inhibitor omapatrilat in spontaneously hypertensive rats
    Wei, CM
    Dong, YF
    Zhou, H
    Shaffer, E
    Liao, WC
    McLaughlin, JS
    FASEB JOURNAL, 2001, 15 (04): : A466 - A466
  • [10] Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease
    Dudman, N
    Hunt, D
    MacMahon, S
    Neal, B
    Richards, M
    Simes, J
    Tonkin, A
    Wilcken, D
    Murphy, J
    Cleverly, Y
    Keech, A
    Ohkubo, T
    Brnabic, A
    Tonkin, A
    Bos, K
    Bartram, H
    Bennett, D
    Broad, J
    Douglas, D
    Fisher, S
    Gray, B
    Milne, A
    McCulloch, A
    Ng, C
    Pledger, M
    Pryor, A
    Santos, A
    Slater, A
    Yiu, K
    Woodward, M
    Burrell, L
    Brown, L
    Hamer, A
    Roberts, L
    Jeffery, I
    Taverner, P
    Kam, A
    Aylward, P
    Wollaston, F
    Whitehead, A
    Lane, G
    Tulloch, G
    Forrest, N
    Garrett, J
    Aroney, G
    Hicks, P
    Silberberg, J
    Gordon, A
    Holliday, J
    Hicks, L
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2002, 3 (04) : 270 - 276
12345